Kuwanon G

Kuwanon G is a flavonoid compound and an antagonist of the bombesin receptor. Kuwanon G has multiple activities such as bactericidal, anti-tumor, anti-inflammatory, antioxidant, anti-atherosclerotic, and neuroprotective effects. Kuwanon G exhibits strong antibacterial activity against oral pathogens, especially cariogenic bacteria and periodontal pathogens. Kuwanon G can induce apoptosis and inhibit proliferation, migration, and invasion of tumor cells. Kuwanon G can be used in the research of diseases such as gastric cancer and atherosclerosis^{[1][2][3][4][5]}. In Vitro:Kuwanon G (5-70 μM; 48 h) can inhibit the apoptosis of HT22 cells induced by Advanced glycation end products (HY-NP165) and the elevation of MDA and ROS levels, and restore the intracellular Ach level. The mechanism involves the PI3K/Akt/GSK3αβ signaling pathway^[1].
Kuwanon G (0-20 μg/mL; 0-10 min) has an MIC of 8.0 μg/mL for Streptococcus mutans^[2].
Kuwanon G (0-160 μM; 1-24 h) can inhibit the proliferation, migration and invasion, promote cell apoptosis, and inhibit the expression of MMP2 and MMP9 in gastric cancer cells. The mechanism involves the inhibition of the PI3K/AKT/mTOR pathway^[3].
Kuwanon G (2-20 μM; 24 h) can inhibit lipid accumulation and the mRNA levels of inflammatory factors in RAW 264.7 cells treated with ox-LDL (HY-NP135). The mechanism involves the activation of the LXRα-ABCA1/ABCG1 pathway and the inhibition of NF-κB^[4]. In Vivo:Kuwanon G (20-40 μM; 2 weeks) exhibits anti-tumor activity in the MGC 803 xenograft mouse model^[3].
Kuwanon G (5 mg/kg; intraperitoneal injection; once every other day; 16 weeks) has an ameliorative effect in the atherosclerotic mouse model of ApoE^-/- fed a high-fat diet^[4].